Date | Price Target | Rating | Analyst |
---|---|---|---|
9/30/2024 | $20.00 | Sector Outperform | Scotiabank |
9/10/2024 | $15.00 | Mkt Outperform | JMP Securities |
7/9/2024 | $18.00 | Buy | Craig Hallum |
5/23/2024 | $21.00 | Overweight | Cantor Fitzgerald |
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced the appointment of Puneet S. Arora, MD, MS, FACE, as Chief Medical Officer (CMO). "We are thrilled to welcome Dr. Puneet Arora as the Chief Medical Officer at Skye at this pivotal moment in our journey, particularly with the initiation of the Phase 2 CBeyond™ obesity clinical trial for nimacimab, our differentiated CB1 inhibitor," said Punit Dhillon, Skye's CEO and Chair. "Dr. Arora is well-regarded in the industry, brings extensive experience in designing and executing cli
SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today reported financial results for the second quarter ended June 30, 2024, and highlighted recent corporate achievements. "Our strategic acquisition of nimacimab in August 2023 has propelled Skye into the metabolic landscape, where there is a need to provide patients with obesity more tolerable and sustainable therapeutic alternatives to manage weight loss and address comorbid conditions," said Punit Dhillon, CEO of Skye. "In Q2, at our event, ‘Metabolic Rewiring wi
SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced the appointment of Karen Smith, MD, Ph.D., MBA, LLM to its Board of Directors. Dr. Smith brings significant global biotech and biopharma leadership experience, complementing the Company's operational and clinical expertise. Our strategic focus on the Nimacimab metabolic program will be supported by an evolving board as Keith Ward, PhD, and Praveen Tyle, PhD, resign from their roles as Boa
4 - Skye Bioscience, Inc. (0001516551) (Issuer)
4 - Skye Bioscience, Inc. (0001516551) (Issuer)
4 - Skye Bioscience, Inc. (0001516551) (Issuer)
16-week top-line weight loss data validates mechanism of action targeting peripheral CB1 receptors Skye highlights safety advantages of large-molecule CB1 inhibition compared to small-molecule approach SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on developing new therapeutics for metabolic health, is providing a statement regarding a recent announcement by Novo Nordisk on Phase 2a top-line data with monlunabant, Novo's small-molecule oral cannabinoid receptor (CB1) inverse agonist. "We are encouraged to see that monlunabant met its primary endpoint and demonstrated at least a 6% placebo-ad
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced the appointment of Puneet S. Arora, MD, MS, FACE, as Chief Medical Officer (CMO). "We are thrilled to welcome Dr. Puneet Arora as the Chief Medical Officer at Skye at this pivotal moment in our journey, particularly with the initiation of the Phase 2 CBeyond™ obesity clinical trial for nimacimab, our differentiated CB1 inhibitor," said Punit Dhillon, Skye's CEO and Chair. "Dr. Arora is well-regarded in the industry, brings extensive experience in designing and executing cli
SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that it will participate in the following upcoming healthcare investment conferences: Morgan Stanley, Friday, September 6, 1x1 meetings (New York)Cantor Global Healthcare Conference, Thursday, September 19, 8:35 am ET, presentation + 1x1 meetings (New York)Bank of America World Medical Innovation Forum, Tuesday, September 24, panel + 1x1 meetings (Boston) Available webcasts will be accessible on Skye's website. About Skye Bioscience Skye i
SC 13G - Skye Bioscience, Inc. (0001516551) (Subject)
Craig-Hallum analyst Albert Lowe initiates coverage on Skye Bioscience (NASDAQ:SKYE) with a Buy rating and announces Price Target of $18.
Scotiabank initiated coverage of Skye Bioscience with a rating of Sector Outperform and set a new price target of $20.00
JMP Securities initiated coverage of Skye Bioscience with a rating of Mkt Outperform and set a new price target of $15.00
Craig Hallum initiated coverage of Skye Bioscience with a rating of Buy and set a new price target of $18.00
DEF 14A - Skye Bioscience, Inc. (0001516551) (Filer)
PRE 14A - Skye Bioscience, Inc. (0001516551) (Filer)
8-K - Skye Bioscience, Inc. (0001516551) (Filer)